Economic value of high-energy, high-protein oral nutritional supplements in disease-related malnutrition in the French community setting.
- 1Nutricia Nutrition Clinique, Rueil-Malmaison, France.
- 2Nutricia Global, Hoofddorp, Netherlands.
- 3Clarivate Analytics, London, United Kingdom.
Abstract
Despite growing evidence supporting nutritional interventions, the comparative economic value of the highest high-energy, high-protein (H-HEHP) oral nutritional supplements (ONS) vs. standard ONS (S-ONS) formulations remains insufficiently characterized. This study evaluated the cost impact of H-HEHP ONS vs. S-ONS in community-dwelling patients with frailty/sarcopenia and disease-related malnutrition (DRM) in France, using a cost calculator to estimate total annual costs and key drivers under current and alternative market-share scenarios. A cost analysis was conducted from the French public healthcare payer perspective over a 1-year time horizon. A deterministic Excel-based cost calculator, informed by a systematic literature review and national demographic and cost data, was used to estimate hospitalization-related costs associated with H-HEHP ONS vs. S-ONS in community-dwelling patients with frailty or sarcopenia and DRM. Current and alternative market-share scenarios were evaluated; robustness of results was assessed using one-way sensitivity analyses. Treatment with H-HEHP ONS at the 2024 market share (73%) within the overall ONS market in community-dwelling patients with frailty/sarcopenia and DRM would generate annual cost savings of €17.4 million compared with S-ONS alone in the French community setting. Per-patient savings of €74 were driven primarily by shorter length of hospital stay and fewer readmissions. Increasing H-HEHP ONS market share to 80% in the community setting would generate an additional €1.7 million annually beyond current utilization. The cost savings identified in this analysis provide valuable information to guide healthcare decision making. As healthcare systems continue to balance competing priorities within constrained budgets, this study supports H-HEHP ONS as a cost-saving intervention, providing population data essential for informed formulary and reimbursement decisions.
Related
- Practical Approaches to Nutritional Interventions for Malnutrition, Sarcopenia, and Frailty in Community-Dwelling Older Adults and Care Home Populations: A Narrative Review
- Metabolic complexity and nutritional reductionism. Deconstructing the single active ingredient paradigm in protein and amino acid supplements.
- Economic evaluation protocol of the Ntshembo (Hope) Trial (RCT) in rural and urban South Africa: an intervention to optimise adolescence body mass index (BMI) pre-conception to address the triple burden of malnutrition
- Impact of malnutrition and nutritional support on infectious complications in critically ill infants and children
- Dietary modification and nutritional supplements for exercise-induced bronchoconstriction: a systematic review and meta-analysis
BibTeX
@article{carot2026economic,
title = {{Economic value of high-energy, high-protein oral nutritional supplements in disease-related malnutrition in the French community setting.}},
author = {Valérie Carot and Aditya Dular and Marie Le Novere and Laetitia Schmitt},
journal = {Frontiers in nutrition},
year = {2026},
month = oct,
doi = {10.3389/fnut.2026.1952501},
url = {https://europepmc.org/article/MED/42952732},
note = {CC BY},
}
RIS
TY - JOUR
TI - Economic value of high-energy, high-protein oral nutritional supplements in disease-related malnutrition in the French community setting.
AU - Valérie Carot
AU - Aditya Dular
AU - Marie Le Novere
AU - Laetitia Schmitt
PY - 2026
DA - 2026/10/14
JO - Frontiers in nutrition
DO - 10.3389/fnut.2026.1952501
UR - https://europepmc.org/article/MED/42952732
AB - Despite growing evidence supporting nutritional interventions, the comparative economic value of the highest high-energy, high-protein (H-HEHP) oral nutritional supplements (ONS) vs. standard ONS (S-ONS) formulations remains insufficiently characterized. This study evaluated the cost impact of H-HEHP ONS vs. S-ONS in community-dwelling patients with frailty/sarcopenia and disease-related malnutrition (DRM) in France, using a cost calculator to estimate total annual costs and key drivers under current and alternative market-share scenarios. A cost analysis was conducted from the French public healthcare payer perspective over a 1-year time horizon. A deterministic Excel-based cost calculator, informed by a systematic literature review and national demographic and cost data, was used to estimate hospitalization-related costs associated with H-HEHP ONS vs. S-ONS in community-dwelling patients with frailty or sarcopenia and DRM. Current and alternative market-share scenarios were evaluated; robustness of results was assessed using one-way sensitivity analyses. Treatment with H-HEHP ONS at the 2024 market share (73%) within the overall ONS market in community-dwelling patients with frailty/sarcopenia and DRM would generate annual cost savings of €17.4 million compared with S-ONS alone in the French community setting. Per-patient savings of €74 were driven primarily by shorter length of hospital stay and fewer readmissions. Increasing H-HEHP ONS market share to 80% in the community setting would generate an additional €1.7 million annually beyond current utilization. The cost savings identified in this analysis provide valuable information to guide healthcare decision making. As healthcare systems continue to balance competing priorities within constrained budgets, this study supports H-HEHP ONS as a cost-saving intervention, providing population data essential for informed formulary and reimbursement decisions.
SN - 2296-861X
ER -